On this week’s episode of Biotech Hangout, hosts Daphne Zohar, Tim Opler, Brad Loncar, Brian Skorney and Michal Preminger discuss the latest industry news including how the state of biotech M&A is tracking and the potential impact of the FTC’s two new proposed rules – plus the latest on Amgen and Horizon’s FTC lawsuit. The hosts also cover private equity financings, including Taysha Gene Therapies’ PIPE and the background behind Biogen’s bid to acquire Reata. Additional coverage includes data and regulatory updates (Seagen, Pfizer, Delcath, Galecto, 2seventy bio) as well as how the FDA weighs mixed data against high patient need, most recently with approval of palovarotene. Other topics include Blue Shield of California partnering with various companies (Amazon, Cost Plus Drug, etc.) to handle drug delivery and bispecific drug pricing. *This episode aired on August 18th, 2023
